...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Transplantation of Discordant Xenogeneic Islets Using Repeated Therapy with Anti-CD154.
【24h】

Transplantation of Discordant Xenogeneic Islets Using Repeated Therapy with Anti-CD154.

机译:使用抗CD154的重复疗法对异种异种胰岛进行移植。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND.: Costimulatory blockade has been shown to allow long-term survival of xenogeneic islets. The aim of the present study was to analyze the possibility of xenogeneic islet retransplantation using costimulatory blockade. METHODS.: Streptozotocin-induced diabetic C57/BL6 mice were transplanted with 1000 human islet equivalents. After 14 days, mice were nephrectomized (graftectomy) and retransplanted with human leukocyte antigen (HLA)-mismatched human islets under contralateral kidney capsule. Four groups were performed: I: all transplants (Tx) without MR1; II: first Tx without MR1, second Tx with MR1; III: first Tx with MR1, second Tx without MR1; and IV: all Tx with MR1. Recipient serums were analyzed by cross-match for serum-mediated cytotoxicity against human lymphocytes and islets. RESULTS.: In group I, the second graft rejection was accelerated (graft survival, 5 +/- 3 days) compared with the first graft without MR1 (13 +/- 7 days). In groups II and III, second graft survivals were 16 +/-1 3 and 62 +/- 15 days, respectively. In group IV, second graft function was maintained for >100 days. Pretransplant cross-matches were all negative. Post-second Tx cross-matches were positive in groups I and II and negative in group IV. In group III, post-second Tx cross-matches were negative only for cells with HLA molecules present in the first donor. CONCLUSIONS.: MR1 was unable to induce tolerance after sensitization. MR1 given at the first Tx only allowed prolonged survival of the second Tx, but rejection still occurred with development of antibodies against molecules not present on first donor cells, indicating that costimulatory blockade does not induce linked-suppression against species-specific antigens of xenografts but can induce donor-specific unresponsiveness. MR1 given for all sequential transplantation allowed long-term regraft survival and prevented occurrence of antidonor antibodies.
机译:背景:共刺激性阻断已被证明可以使异种胰岛长期存活。本研究的目的是分析使用共刺激封锁异种胰岛再移植的可能性。方法:链脲佐菌素诱导的糖尿病C57 / BL6小鼠移植了1000人胰岛当量。 14天后,对小鼠进行肾切除术(移植物切除术),并在对侧肾囊下将人类白细胞抗原(HLA)错配的人类胰岛重新移植。进行四组:I:无MR1的所有移植物(Tx); II:没有TMR的第一个Tx,有MR1的第二个Tx; III:第一个具有MR1的Tx,第二个没有MR1的Tx; IV:所有带有MR1的Tx。通过交叉匹配分析接受者血清对人淋巴细胞和胰岛的血清介导的细胞毒性。结果:与没有MR1的第一个移植物(13 +/- 7天)相比,在第一组中,第二个移植物排斥反应加速(移植物存活,5 +/- 3天)。在第二组和第三组中,第二移植物存活分别为16 +/- 1 3和62 +/- 15天。在IV组中,第二移植物功能维持> 100天。移植前交叉比赛均为阴性。 I和II组第二次Tx交叉匹配为阳性,IV组为阴性。在第三组中,仅对于第一个供体中存在HLA分子的细胞,第二次Tx交叉匹配为阴性。结论:敏化后MR1不能诱导耐受。在第一个Tx处给予MR1只能延长第二个Tx的生存时间,但是随着针对第一个供体细胞上不存在的分子的抗体的发展,排斥反应仍然发生,这表明共刺激性封锁不会诱导针对异种移植物的物种特异性抗原的连锁抑制,但是可以诱发供体特异性的无反应性。所有顺序移植均给予MR1,可以长期移植存活,并防止出现抗供体抗体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号